QZQian Zhao

Qian Zhao

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Qian Zhao has a total of 35 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Cost-effectiveness analysis of depression case finding followed by alerting patients and their GPs among older adults in northern England: results from a regression discontinuity study

    by Qian Zhao, David John Torgerson, Kerry Jane Bell, Joy Ann Adamson, Caroline Marie Fairhurst, Sarah Cockayne, Jennie Lister, Kalpita Baird, David Ekers

    Background: In the UK, around 1 in 4 adults over 65 years suffers from depression. Depression case finding followed by alerting patients and their general practioners (GPs) (screening + GP) is a promising strategy to facilitate depression management, but its cost-effectiveness remains unclear. Aims: To investigate the cost-effectiveness of screening + GP compared with standard of care (SoC) in northern England. Method: Conducted alongside the CASCADE study, 1020 adults aged 65+ years were recruited. Participants with baseline Geriatric Depression Scale (GDS) ≥5 were allocated to the intervention arm and those >5 to SoC. Resource use and EQ-5D-5L data were collected at baseline and 6 months. Incremental cost-effectiveness ratio was calculated. Non-parametric bootstrapping was performed to capture sampling uncertainty. The results are presented using cost-effectiveness acceptability curves. Sensitivity analyses were conducted to assess the robustness of primary findings. Subgroup analyses were undertaken to examine the cost-effectiveness among participants with more comparable baseline characteristics across treatment groups. Results: Screening + GP incurred £37 more costs and 0.006 fewer quality-adjusted life years than SoC; the probability of the former being cost-effective was <5% at a £30 000 cost-effectiveness threshold. Sensitivity analyses confirmed the base-case findings. Subgroup analyses indicated that screening + GP was cost-effective when patients with baseline GDS 2–7, 3–6 and 4–5, respectively, were analysed. Conclusions: Screening + GP was dominated by SoC in northern England. However, subgroup analyses suggested it could be cost-effective if patients with more balanced baseline characteristics were analysed. Economic evaluations alongside randomised controlled trials are warranted to validate these findings.

  • Open Access

    Intermittent Fasting Inhibits High-Fat Diet–Induced Atherosclerosis by Ameliorating Hypercholesterolemia and Reducing Monocyte Chemoattraction

    by Yuanli Chen, Jiamin Su, Yali Yan, Qian Zhao, Jialing Ma, Mengmeng Zhu, Xiaoyu He, Baotong Zhang, Hongmei Xu, Xiaoxiao Yang, et al.

    Atherosclerosis is a major pathology for cardiovascular diseases (CVDs). Clinically, the intermittent fasting (IF) has been observed to reduce the risk of CVDs. However, the effect of IF on the development of atherosclerosis has not been fully elucidated. Herein, we determined the protection of IF against high-fat diet–induced atherosclerosis in pro-atherogenic low-density lipoprotein receptor deficient (LDLR-/-) mice and the potentially involved mechanisms. The LDLR-/- mice were scheduled intermittent fasting cycles of 3-day HFD feeding ad libitum and 1 day fasting, while the mice in the control group were continuously fed HFD. The treatment was lasted for 7 weeks (∼12 cycles) or 14 weeks (∼24 cycles). Associated with the reduced total HFD intake, IF substantially reduced lesions in the en face aorta and aortic root sinus. It also increased plaque stability by increasing the smooth muscle cell (SMC)/collagen content and fibrotic cap thickness while reducing macrophage accumulation and necrotic core areas. Mechanistically, IF reduced serum total and LDL cholesterol levels by inhibiting cholesterol synthesis in the liver. Meanwhile, HFD-induced hepatic lipid accumulation was attenuated by IF. Interestingly, circulating Ly6Chigh monocytes but not T cells and serum c-c motif chemokine ligand 2 levels were significantly reduced by IF. Functionally, adhesion of monocytes to the aortic endothelium was decreased by IF via inhibiting VCAM-1 and ICAM-1 expression. Taken together, our study indicates that IF reduces atherosclerosis in LDLR-/- mice by reducing monocyte chemoattraction/adhesion and ameliorating hypercholesterolemia and suggests its potential application for atherosclerosis treatment.


  • Pharmacokinetics, Pharmacodynamics, Safety, and Clinical Activity of Multiple Doses of RCT‐18 in Chinese Patients With Systemic Lupus Erythematosus

    by Qian Zhao, Xia Chen, Yong Hou, Ji Jiang, Wen Zhong, Xuejing Yao, Wenxiang Wang, Lin Li, Jianmin Fang, Fengchun Zhang, et al.

    RCT‐18 is a novel recombinant fusion protein that blocks the activity of a B‐lymphocyte stimulator and a proliferation‐inducing ligand. This was a randomized, single‐blind, and placebo‐controlled phase 1 study in 12 patients with systemic lupus erythematosus. Eligible patients were randomized 3:1 to receive multiple subcutaneous doses of RCT‐18 for 4 weeks (180 mg, once weekly) or placebo and monitored over an 84‐day observation period for pharmacokinetics, pharmacodynamics, immunogenicity, safety, and clinical activity. After multiple‐dose RCT‐18, the maximal serum concentration (Cmax) of total and free RCT‐18 was reached within 1 to 2 days. Mean elimination half‐life for total RCT‐18 and free RCT‐18 was 11.4 to 26.4 days and 2.4 to 26.5 days, respectively. Slight accumulation was found after multiple subcutaneous administrations. The average accumulation ratios of AUC and Cmax after the fourth administration of RCT‐18 were 2.0 and 1.7 for total RCT‐18, and 1.8 and 1.6 for free RCT‐18. The formation and elimination of BLyS‐RCT‐18 complex were much slower, with a time to Cmax of 14 to 46 days. Pharmacokinetic characteristics of RCT‐18 in SLE patients were similar to those in patients with rheumatoid arthritis. No positive reaction was detected in the immunogenicity assessments. RCT‐18 was biologically active, according to serum immunoglobulin and B‐cell levels. Treatment‐related IgM and IgA reduction was found during this study. CD19+, IgD+, and CD27+ B‐cell counts were increased after administration and decreased subsequently. SLE patients treated with RCT‐18 were more prone to infections, including moderate and severe infections. Lower dosages of RCT‐18 should be considered in further clinical development.


  • Effect of the postictal state on visual-spatial memory in immature rats

    by Olia Boukhezra, Peter Riviello, Dong Dong Fu, Xianzeng Lui, Qian Zhao, Cigdem Akman, Gregory L Holmes